• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Aromasin (exemestane) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) –

February 2013

Summary View

 

WARNINGS AND PRECAUTIONS

Vitamin D Assessment
  • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer (EBC). Women with vitamin D deficiency should receive supplementation with vitamin D.
 

ADVERSE REACTIONS

Postmarketing Experience
  • hypersensitivity
  • urticaria
  • pruritis

 

March 2011 

Summary View

 

ADVERSE REACTION

  • adverse event information to the labeling based on 52 months of median follow-up in study 96-OEXE 031
Post-Marketing Experience
  • addition of information cholestatic hepatitis